We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




C. Difficile Colonization Among Children in Resource-Limited Settings

By LabMedica International staff writers
Posted on 02 Mar 2022

This study describes the epidemiology and risk factors for colonization among children in the etiology, risk factors, and interactions of enteric infections and malnutrition. Also explored was whether C. difficile detection contributed to longer-term health outcomes.


Clostridioides difficile
is a bacterium that causes severe diarrhea and colitis. It’s estimated to cause almost half a million infections in the USA each year. About 1 in 6 patients who get C. diff will get it again in the subsequent 2-8 weeks. One in 11 people over age 65 diagnosed with a healthcare-associated C. diff infection die within one month.

High rates of C. difficile colonization have been documented among infants in resource sufficient settings, where C. difficile infection (CDI) rates can be as high as 90% among hospitalized neonates. Colonization decreases with increasing age until age two when rates start to mirror healthy adults. Some studies have indicated that C. difficile may be more prevalent than rotavirus or Cryptosporidium in children presenting with diarrhea to the hospital.

Infectious Disease specialists at The University of Virginia School of Medicine (Charlottesville, VA, USA) conducted a study at eight sites: Dhaka, Bangladesh; Fortaleza, Brazil; Vellore, India; Bhaktapur, Nepal; Loreto, Peru; Naushero Feroze, Pakistan; Venda, South Africa; and Haydom, Tanzania. The study ran from November 2009 through February 2014. The team tested 41,354 monthly non-diarrheal and diarrheal stools for C. difficile toxin genes (tcdA and tcdB) using quantitative polymerase chain reaction (qPCR) in 1,715 children from birth to age two years.

The QIAmp Fast DNA Stool Mini Kit (Qiagen, Venlo, The Netherlands) was used to extract total nucleic acid from the stool specimens. TaqMan Array Cards (TAC) were developed to detect 29 enteropathogens via qPCR using AgPath One Step Realtime PCR kit (Thermo Fisher Scientific, Waltham, MA, USA). The qPCR assays targeting C. difficile tcdA (enterotoxin) and tcdB (cytotoxin) genes were validated on the TaqMan Array platform, demonstrating 100% sensitivity and 100% specificity on clinical specimens using a secondary real time PCR as confirmation.

Monthly stool samples were tested for myeloperoxidase (MPO; measured in ng/m), neopterin (NEO; measured in nmol/L), and α-1-antitrypsin (AAT; measured in mg/g) and analyzed on the logarithmic scale. Serum α-1-acid glycoprotein was measured at months 7, 15, and 24 (AGP; measured in mg/dL). Lactulose/mannitol excretion ratios (LMR) were measured in urine at 3, 6, 9, and 15 months. Plasma zinc and retinol were measured at 7, 15, and 24 months.

The scientists reported that the prevalence of C. difficile detection was lower in diarrheal (2.2%; n= 151/6,731) compared to non-diarrheal stools (6.1%; n= 2106/34,623). By 24 months of age, the cumulative incidence of C. difficile varied widely by site, ranging from 17.9% (n=44; Pakistan) to 76.3% (n=148; Peru) of children having at least one positive stool. Only Bangladesh and Pakistan had seasonal differences in C. difficile detection. Female gender (adjusted risk ratio (aRR):1.18), cephalosporin use in the past 15 days (aRR: 1.73), and treated water (aRR: 1.24) were risk factors for C. difficile positivity. C. difficile carriage was significantly associated with elevated fecal myeloperoxidase, neopterin, and α-1-antitrypsin, but no associations were found between C. difficile and child growth at 24 months of age.

The authors concluded that C. difficile colonization among children ages 0-2 years was variable across low-resource settings. Significant elevation of intestinal inflammation and barrier disruption markers associated with C. difficile detection suggests subclinical impact of colonization. The study was published on February 09, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
University of Virginia School of Medicine 
Qiagen
Thermo Fisher Scientific


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.